Pharmaceuticals

Sage and Biogen halt Phase 2 trial of new drug after failure to show significant improvement in treating essential tremor

bexib
By bexib 0 Min Read

Going forward, Sage Therapeutics and Biogen plan to discontinue further clinical development of SAGE-324 for essential tremor.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Measuring inequality from multiple angles
Next Article Delta Air Lines expects flight disruptions to ease and operations to return to normal by Thursday Reuters – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

A look inside: Allies developing a multicloud hybrid strategy
Banking
2024 Holiday Shipping Deadline for the United States
International Shipping
Ecommerce taxes – How to stay ahead of the sales tax maze
Retail & E-commerce
Finastra breach: 3 security points
Banking